Volume 12 - Issue 9 - September, 2004

Shore Memorial Hospital: Faster and More Efficient Workflow

Shore Memorial is the only local hospital offering a clinical affiliation with the University of Pennsylvania Health System. Through this affiliation, cardiologists from PENN Cardiac Care at University of Pennsylvania Medical Center-Presbyterian provide diagnostic catheterization services on-site in Shore Memorial’s recently opened CardioVascular Institute (CVI).

The CVI is located on the hospital’s second floor. An $8.5 million Institute, it includes some of the most advanced technology available and a team of nurses, technologists, cardiologists, radiologists and vascular surgeons se

Angiolink's Staple-Mediated VCD Addresses Limitations of Current Technology Part II

We designed the staple with a surgeon’s mentality, and chose titanium as the metal. Titanium is a very cheap, very inert metal that actually is what surgeons will implant most of the time with heart valves and with hip replacements. The staple is a very small, low-profile 3-mm staple. Figure 2 is really 3 millimeters, and portion A is designed to sit above the artery. The B portion is designed to actually implant into the outer walls of the vessel, avoiding the lumen of the vessel. This VCD is totally extraluminal in its action, which is one of its major advantages.

Closing the Vesse

A New Perspective on an Old Standard

Cath Lab Digest will, on occasion, publish an article that looks at an accepted issue or standard in an outside-the-box kind of way. We are fortunate to have such an article by Dr. David Allie this month, titled: Vascular Access Site Hemostasis: ‘An Endovascular Surgeon’s Perspective’ Manual Compression May Not Be Benign! Dr. Allie compares the state of today’s vascular closure devices with the beginning of the coronary stent era, and calls for more industry investment in an ideal vascular closure device.

By virtue of his background as a vascular surgeon, one important implica

Clinical and Industry News

Boston Scientific Announces FDA Clearance for Peripheral Cutting Balloon Microsurgical Dilatation Devices

Device Dilates Lesions at Lower Pressures than Traditional Angioplasty

Boston Scientific Corporation has received clearance from the U.S. Food and Drug Administration (FDA) to market its Peripheral Cutting Balloon microsurgical dilatation device in the United States. The Company will launch the device immediately.

The Peripheral Cutting Balloon device features tiny, longitudinally mounted atherotomes (microsurgical blades) on the surface of an angioplasty balloon and will

A Minimally Invasive, Mechanical Cardiovascular Support System

What is the Impella® Recover® LP 2.5 System?

The Impella Recover LP 2.5 device is a percutaneous ventricular unloading catheter. This is a 12-French catheter, placed in the left ventricle, which utilizes a transaxial flow pump to transfer blood from the left ventricle into the ascending aorta. The pump can deliver as much as 2.5 liters of blood per minute. Essentially, the Recover LP 2.5 System increases cardiac output, thereby increasing end-organ perfusion. In addition, by unloading the left ventricle, it reduces myocardial workload and oxygen consumption. We suspect that this